RLMDRelmada Therapeutics, Inc.

Healthcare
$3.16+59% 1Y

The financials

Relmada Therapeutics, Inc. by the numbers

The next results filing is expected around Nov 12, 2026, the same week as a year ago.

Relmada Therapeutics, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Operating income−$15M−$10Mn/a
Net income−$13M−$9.9Mn/a
Diluted EPS−$0.11−$0.30n/a

Biotechnology

Ranks #171 of 196 by RyuScore

Compare peers
ARTV-2.9%
Artiva Biotherapeutics, Inc.
OCGN-1.8%
Ocugen, Inc.
SRZN+12%
Surrozen, Inc./DE
TTRX-5.0%
Turn Therapeutics Inc.
OBIO+0.88%
Orchestra BioMed Holdings, Inc.
CABA-2.0%
Cabaletta Bio, Inc.